Abstract Purpose Cyclosporine A (CsA) and imatinib are both CYP3A4 and P-glycoprotein
substrates. Concomitant use after hematopoietic stem cell transplantation (HSCT) for chronic …

Background First-generation ABL-targeted tyrosine kinase inhibitor (TKI) imatinib is known
to retard growth in children but it is not known if the second-generation ABL-targeted TKI …

Since the introduction of imatinib, tyrosine kinase inhibitors (TKIs) have become key drugs
for treating chronic myeloid leukemia (CML). 1 Although TKIs used for CML were specifically …

Cancer morbimortality is still a great concern despite advances in research and therapies.
Histamine and its receptors' ligands can modulate different biological responses according …

Despite the excellent efficacy and improved clinical responses obtained with imatinib
mesylate (IM), development of resistance in a significant proportion of chronic myeloid …

The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for
HIV and cancer patients. To address this, current literature and guidelines suggest the …

The advent of targeted therapeutics has greatly improved outcomes of chronic myeloid
leukemia (CML) patients. Despite increased efficacy and better clinical responses over …

Portal vein thrombosis (PVT) refers to the development of a non-malignant obstruction of the
portal vein, its branches, its radicles, or a combination. This Review first provides a …

ABSTRACT Introduction Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates
of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute …

Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United
States for the treatment of chronic myeloid leukemia in chronic or accelerated phase …